第 1 到 19 筆結果,共 19 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2023 | Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma | BANG-BIN CHEN ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH ; TSUNG-HAO LIU ; YING-CHUN SHEN ; LI-CHUN LU ; ZHONG-ZHE LIN ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; YU-YUN SHAO | European radiology | 20 | 13 | |
2 | 2022 | Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment | Chen, Ching-Tso; Feng, Yin-Hsun; Yen, Chia-Jui; Chen, San-Chi; Lin, Yun-Tzu; LI-CHUN LU ; CHIH-HUNG HSU ; ANN-LII CHENG ; YU-YUN SHAO | Hepatology international | 14 | 14 | |
3 | 2022 | ICOS-Positive Regulatory T Cells in Hepatocellular Carcinoma: The Perspective from Digital Pathology Analysis | LI-CHUN LU ; Deantonio, Cecilia; Palu, Cintia C; Lee, Yi-Hsuan; Mitchell, Laura S; Cowan, Marianne; Corser, Matthew; Sherry, Lorcan; ANN-LII CHENG ; Quaratino, Sonia; YU-YUN SHAO ; Sainson, Richard C A; CHIH-HUNG HSU | Oncology (Switzerland) | 1 | 0 | |
4 | 2021 | Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy | YING-CHUN SHEN ; Yeh C.-P.; YUNG-MING JENG ; CHIUN HSU ; CHIH-HUNG HSU ; ZHONG-ZHE LIN ; YU-YUN SHAO ; LI-CHUN LU ; TSUNG-HAO LIU ; CHIEN-HUNG CHEN ; ANN-LII CHENG | Cancers | 2 | 2 | |
5 | 2021 | Solving the deficit of cancer pain management skills by education programs | YU-YUN SHAO ; WEN-YING LIN ; CHIH-PENG LIN ; LI-CHUN LU ; CHIH-HUNG HSU | Supportive Care in Cancer | 2 | 2 | |
6 | 2019 | Considerations of heterogeneity in clinical trials for hepatocellular carcinoma | TSUNG-HAO LIU ; YU-YUN SHAO ; LI-CHUN LU ; Ying-Chun Shen ; CHIUN HSU ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; ANN-LII CHENG | Expert Review of Gastroenterology and Hepatology | 5 | 7 | |
7 | 2019 | Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment | LI-CHUN LU ; Lee, Yi Hsuan; Chang, Chun Jung; CHIA-TUNG SHUN ; Fang, Chih Yeu; YU-YUN SHAO ; TSUNG-HAO LIU ; ANN-LII CHENG ; CHIH-HUNG HSU | Liver Cancer | 45 | 41 | |
8 | 2019 | Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma | LI-CHUN LU ; CHIUN HSU ; YU-YUN SHAO ; Chao Y.; Yen C.-J.; I-LUN SHIH ; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen ; JHE-CYUAN GUO ; TSUNG-HAO LIU ; CHIH-HUNG HSU ; ANN-LII CHENG | Liver Cancer | 46 | 44 | |
9 | 2019 | Early alpha‐foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma | YU-YUN SHAO ; TSUNG-HAO LIU ; CHIUN HSU ; LI-CHUN LU ; YING-CHUN SHEN ; ZHONG-ZHE LIN ; ANN-LII CHENG ; CHIH-HUNG HSU | Liver International | 58 | 58 | |
10 | 2017 | Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study | LI-CHUN LU ; PEI-JER CHEN ; Yeh Y.-C.; CHIH-HUNG HSU ; Chen H.-M.; Lai M.-S.; YU-YUN SHAO ; ANN-LII CHENG | Anticancer Research | 15 | 16 | |
11 | 2016 | Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma | Lin H.-H.; Feng W.-C.; LI-CHUN LU ; YU-YUN SHAO ; CHIH-HUNG HSU ; ANN-LII CHENG | Cancer letters | 37 | 39 | |
12 | 2015 | Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials | YU-YUN SHAO ; Shau, W.-Y.; Chan, S.-Y.; LI-CHUN LU ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology (Switzerland) | 30 | 29 | |
13 | 2014 | β-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma | LI-CHUN LU ; YU-YUN SHAO ; Lee Y.-H.; MIN-SHU HSIEH ; Hsiao C.-H.; Lin H.-H.; HSIANG-FONG KAO ; Ma Y.-Y.; Yen F.-C.; ANN-LII CHENG ; CHIH-HUNG HSU | Oncology (Switzerland) | 25 | 24 | |
14 | 2014 | Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy | LI-CHUN LU ; YU-YUN SHAO ; Chan S.-Y.; CHIH-HUNG HSU ; ANN-LII CHENG | Anticancer Research | 12 | 10 | |
15 | 2014 | Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy | YU-YUN SHAO ; CHIH-HORNG WU ; LI-CHUN LU ; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; CHIH-HUNG HSU ; ANN-LII CHENG | Journal of Hepatology | 46 | 48 | |
16 | 2013 | Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma | LI-CHUN LU ; YU-YUN SHAO ; Kuo R.N.C.; ZHONG-ZHE LIN ; Yeh Y.-C.; Shau W.-Y.; CHIH-HUNG HSU ; ANN-LII CHENG ; Lai M.-S. | Cancer | 11 | 11 | |
17 | 2012 | Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems | YU-YUN SHAO ; LI-CHUN LU ; ZHONG-ZHE LIN ; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | British Journal of Cancer | 26 | 26 | |
18 | 2012 | Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer | LI-CHUN LU ; YU-YUN SHAO ; CHIH-HUNG HSU ; CHIUN HSU ; WEN-FANG CHENG ; YU-LIN LIN ; ANN-LII CHENG ; KUN-HUEI YEH | Anticancer Research | 0 | ||
19 | 2011 | Increasing incidence of brain metastasis in patients with advanced Hepatocellular carcinoma in the era of Antiangiogenic targeted therapy | YU-YUN SHAO ; LI-CHUN LU ; ANN-LII CHENG ; CHIH-HUNG HSU | Oncologist | 34 | 28 |